EXCLUSIVE: GT Biopharma Achieves Development Milestone for Human Trial for Novel Blood Cancer Therapy
GT Biopharma secures FDA IND clearance for GTB-5550, advancing its TriKE therapy into Phase 1 clinical trials for multiple myeloma.
Share
Why It Matters
GT Biopharma got permission to test a new cancer medicine on people. This is a big step forward, so watch if the company hits future testing goals.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.